Search
                    Coronary Artery Disease Clinical Trials
A listing of 63  Coronary Artery Disease  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 63
        
                There are currently 63 active clinical trials seeking participants for Coronary Artery Disease research studies. The states with the highest number of trials for Coronary Artery Disease participants are Florida, California, New York and Texas.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
                                
            
            
        Recruiting
                            
            
                This is a two-part study, comprised of an initial open-label run-in phase (Part 1) in a subset of 3 subjects to provide first data regarding safety, and feasibility of the percutaneous endovascular catheter-facilitated intramyocardial delivery of XC001 in patients with RA due to obstructive CAD.
Part 1 of the study is comprised of 3 subjects with RA (CCS class II-IV) who will receive 4×1011 viral particles (vp) XC001. An Independent Data Monitoring Committee (IDMC), the committee will review sa...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 85 years
            Trial Updated:
                07/30/2025
            
            Locations: Christ Hospital, Cincinnati, Ohio         
        
        
            Conditions: Refractory Angina, Coronary Artery Disease
        
            
        
    
                
                                    A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
                                
            
            
        Recruiting
                            
            
                PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptom...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/22/2025
            
            Locations: Cardiology Associates of Mobile, Mobile, Alabama  +17 locations         
        
        
            Conditions: Coronary Artery Disease
        
            
        
    
                
                                    Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-48) Study
                                
            
            
        Recruiting
                            
            
                The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm.
Patients enrolled in the United States will be followed for 2 years post index procedure with follow-up visits at 1, 6, 12 months and 2 years post index procedure. Patie...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/18/2025
            
            Locations: Charleston Area Medical Center, Charleston, West Virginia  +1 locations         
        
        
            Conditions: Coronary Artery Disease
        
            
        
    
                
                                    RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
                                
            
            
        Recruiting
                            
            
                This a Phase 3, prospective, open-label, multicenter study of \[15-O\]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants wi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/13/2025
            
            Locations: University of Iowa, Iowa City, Iowa  +12 locations         
        
        
            Conditions: Coronary Artery Disease
        
            
        
    
                
                                    Acceptance and Commitment Therapy for Patients Undergoing Coronary Artery Bypass Graft Surgery
                                
            
            
        Recruiting
                            
            
                Heart disease is the leading cause of death globally, accounting for 16% of the world's total deaths. The number of cases is expected to increase as our population ages. Heart disease also results in large economic burden. It costs the United States about $219 billion per year. Some patients have symptoms that aren't helped by drugs or other medical treatments. These patients will need a surgery that is called cardiac artery bypass graft (CABG) surgery. CABG helps to improve chest pain which is...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                08/07/2025
            
            Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa         
        
        
            Conditions: Coronary Artery Disease, Vascularization
        
            
        
    
                
                                    PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
                                
            
            
        Recruiting
                            
            
                Early detection of coronary atherosclerotic disease facilitates adequate prevention. The purpose of this study is to compare an assessment of coronary atherosclerotic disease burden by positron emission tomography / computed tomography (NaF-PET/CT) with those of conventional and ultra-high-resolution-CT (UHR-CT) in patients with suspected coronary artery disease. For this purpose, the investigators plan to include 33 patients with symptoms concerning for CAD who have been referred for cardiac CT...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/29/2025
            
            Locations: Johns Hopkins Hospital, Baltimore, Maryland         
        
        
            Conditions: Coronary Artery Disease, Atherosclerosis, Coronary Atherosclerosis of Native Coronary Artery
        
            
        
    
                
                                    RADIQAL Study (Radiation Dose and Image Quality Trial)
                                
            
            
        Recruiting
                            
            
                The Azurion R4.0 is developed by Philips Medical Systems Nederland B.V., a Philips Healthcare company. The Azurion is an interventional X-ray system which is used for live X-ray imaging during invasive cardiac procedures. The proposed Azurion R4.0 includes new x-ray image postprocessing (Xres5) compared to its predecessor, which was equipped with ClarityIQ image post-processing (Xres4).
Azurion R4.0 is a cleared device for EU-MDR regulated countries, submission for FDA510K clearance in the US i...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/29/2025
            
            Locations: University of Colorado, Denver, Colorado  +5 locations         
        
        
            Conditions: Coronary Artery Disease
        
            
        
    
                
                                    Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
                                
            
            
        Recruiting
                            
            
                The goal of this randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease on change in cardiovascular health over one year.             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 75 years
            Trial Updated:
                07/28/2025
            
            Locations: Massachusetts General Hospital, Boston, Massachusetts         
        
        
            Conditions: Coronary Artery Disease
        
            
        
    
                
                                    Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
                                
            
            
        Recruiting
                            
            
                The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.             
        
        
    Gender:
                ALL
            Ages:
                Between 40 years and 75 years
            Trial Updated:
                07/28/2025
            
            Locations: Massachusetts General Hospital, Boston, Massachusetts         
        
        
            Conditions: Coronary Artery Disease
        
            
        
    
                
                                    Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
                                
            
            
        Recruiting
                            
            
                The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2025
            
            Locations: Scripps Health, La Jolla, California  +33 locations         
        
        
            Conditions: Coronary Artery Disease, Coronary Artery Calcification
        
            
        
    
                
                                    Product Surveillance Registry
                                
            
            
        Recruiting
                            
            
                The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/24/2025
            
            Locations: Not set, Birmingham, Alabama  +381 locations         
        
        
            Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
        
            
        
    
                
                                    Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
                                
            
            
        Recruiting
                            
            
                Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while...  Read More             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/22/2025
            
            Locations: Huntsville Heart Center, Huntsville, Alabama  +71 locations         
        
        
            Conditions: Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
        
            
        
    1 - 12 of 63
            